This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effects of a Supplement Containing Fucoidan on Basal Body Temperature

This study has been completed.
Three Peace Co., Ltd., Japan
Information provided by (Responsible Party):
Fumiko Higashikawa, Hiroshima University Identifier:
First received: July 19, 2011
Last updated: December 13, 2012
Last verified: December 2012
We aim to determine whether a supplement containing fucoidan isolated from Mekabu (sporophyll of Undaria pinnatifida), EPA, and DHA has effects of elevating basal body temperature in subjects with low basal body temperature.

Condition Intervention
Low Basal Body Temperature Dietary Supplement: Supplement containing fucoidan, EPA, and DHA Dietary Supplement: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Effects of a Supplement Containing Fucoidan as a Major Component on Basal Body Temperature: a Placebo Controlled, Cross-over Study

Resource links provided by NLM:

Further study details as provided by Fumiko Higashikawa, Hiroshima University:

Primary Outcome Measures:
  • Basal body temperature [ Time Frame: up to 20 weeks ]

Secondary Outcome Measures:
  • Change from baseline in serum lipid levels (total cholesterol, LDL cholesterol, HDL cholesterol, and triglyceride) [ Time Frame: Weeks 0, 8, 12, and 20 ]

Enrollment: 19
Study Start Date: July 2011
Study Completion Date: March 2012
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Fucoidan supplement Dietary Supplement: Supplement containing fucoidan, EPA, and DHA
75 mg fucoidan per day, for 8 weeks
Placebo Comparator: Placebo Dietary Supplement: Placebo
for 8 weeks


Ages Eligible for Study:   55 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Postmenopausal women with basal body temperature < 36.0 ºC
  • Healthy as based on medical history and physical examination
  • Willing not to donate blood during the study
  • Informed consent signed

Exclusion Criteria:

  • Renal or hepatic dysfunction
  • Heart disease
  • Participation in any clinical trial within 90 days of the commencement of the trial
  • Subjects who are taking medicines or functional food that may affect basal body temperature
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01399216

Hiroshima University
Hiroshima, Japan, 734-8551
Sponsors and Collaborators
Hiroshima University
Three Peace Co., Ltd., Japan
Principal Investigator: Fumiko Higashikawa, PhD Hiroshima University
  More Information

Responsible Party: Fumiko Higashikawa, Associate Professor, Hiroshima University Identifier: NCT01399216     History of Changes
Other Study ID Numbers: eki-420
Study First Received: July 19, 2011
Last Updated: December 13, 2012

Additional relevant MeSH terms:
Anti-Ulcer Agents
Gastrointestinal Agents
Antineoplastic Agents processed this record on September 20, 2017